DOI: 10.21276/sasjm.2018.4.2.2

Pages: 17-25

Tuberculosis is continuing to be major global health problem, in spite of implementation of effective drug regimen as per RNTCP guide lines. MDR-TB is now a great threat to mankind and drugs challenged against it have potential adverse reactions. If such reactions are not assessed or managed properly, it may lead to repeated drug interruptions and poor outcome. The objective of our study is to assess the causality, severity and preventability of the adverse drug reactions of CAT IV regimen during treatment of MDR-TB patients. It is a prospective hospital based, observational study conducted in DR TB centre, Department of Pulmonary Medicine, SCB Medical College, Cuttack during the period from July 2015 to March 2017. We included 59 newly diagnosed MDR-TB cases having adverse drug reactions after excluding comorbid conditions and other medications. All adverse reactions are identified, diagnosed clinically or by laboratory parameters and assessed during the course of treatment. Majority had single (42.4%) or multiple (44%) adverse drug reactions. The most common adverse drug reaction was Gastritis in 74.6% cases followed by Hearing loss (18.6%), Dizziness (16.9%) and Joint pain (13.6%).